PAM
ZVRA icon

Panagora Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Panagora Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-67,485
Closed -$642K – 1276
2025
Q3 		$642K Buy
+67,485
New +$677K ﹤0.01% 747
2021
Q3 		– Sell
-465
Closed -$6K – 2407
2021
Q2 		$6K Buy
+465
New +$5K ﹤0.01% 2452
2015
Q4 		– Sell
-180
Closed -$56K – 2371
2015
Q3 		$56K Buy
+180
New +$55.1K ﹤0.01% 1966

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Panagora Asset Management's ZVRA Position: Q4 2025 in Review

Panagora Asset Management sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 67,485 shares — an estimated $642K sold.

Panagora Asset Management first reported a position in ZVRA in Q3 2015 and held it in 3 quarters. The position peaked at $642K in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Panagora Asset Management reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Panagora Asset Management sold 67,485 Zevra Therapeutics shares in Q4 2025, an estimated $642K.
  • Panagora Asset Management first reported a position in Zevra Therapeutics in Q3 2015 and held it in 3 quarters.
  • Panagora Asset Management's Zevra Therapeutics position peaked at $642K in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Panagora Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.